埃克替尼治疗晚期肺腺癌的疗效分析

Efficacy of Icotinib for Advanced Lung Adenocarcinoma

目的:观察埃克替尼治疗晚期肺腺癌的疗效及安全性方法:收集2011年7月至2012年3月我院晚期肺腺癌患者共67例,均给予口服埃克替尼125mg,tid,直至疾病进展或出现无法耐受的不良反心。结果:67例中一线治疗者16例,二线及二线以上治疗者51例,总的客观缓解率为35.8%(24/67),疾病控制率为74.6%(50/67);行EGFR(Epidermal growth factor receptor,表皮生长因子受体)基因检测的18例患者中有15例EGFR基因突变阳性,客观缓解率为60%(9/15),疾病控制率为93.3%(14/15)疗效因素分析显示仅化疗方案数与客观有效率和疾病控制率有关系(P=0.034,P=0.044)。最常见的有不良反应皮疹、腹泻、皮肤瘙痒,发生率分别为20.9%、11.9%、9.0%,程度均较轻(Ⅰ度～Ⅱ度)。结论:埃克替尼治疗晚期肺腺癌,患者能获得较好的疗效及临床获益,且安全性好。

Objective： To evaluate the efficacy and safety of Icotinib for advanced lung adenocarcinoma. Methods ： Sixty-sev- en patients with advanced lung adenoearcinoma were collected from July 2011 to March 2012 in our hospital. All of them received Icotinib （125mg） three times a day till disease progression or intolerable adverse events developed. Results： Of 67 patients, 16 patients were treated with Icotinib as the first-line therapy, other 51 patients accepted Ieotinib as the second or over second-line therapy. The o- verall response rate was 35.8% （24/67）, and the disease control rate was 74. 6% （50/67）. Of 15 patients with EGFR （Epidermal growth factor receptor）mutation-positive, the objective response rate was 60. 0% （9/15）, and the disease control rate was 93.3 % （ 14/ 15 ）. The analysis for the influencing factors of clinical efficacy showed that only the number of chemotherapy regimen was significantly relevant to the response rate and the disease control rate（P = 0. 034 ,P = 0. 044）. About adverse events, skin rash, diarrhea and skin itching were observed most frequently, which happened on 20. 9% , 11.9% and 9.0% of patients respectively. But most of them were grade I or I. Conclusion： The treatment of Icotinib for advanced lung adenoearcinoma is safe and may get good efficacy as well as clinical benefit.